Talvinen K et al. - In a study to explore securin as a proliferation marker in invasive ductal breast concer, it was shown that securin immunostaining is a promising and clinically applicable proliferation marker Methods
Securin was analysed in invasive ductal breast carcinomas by cDNA microarrays and immunohistochemistry
Analysis was done in cDNA microarray of a total of 4000 probes of genes
Results
Securin was revealed with a significant change in expression among the several proliferation-related genes studied
Value of securin as a proliferation marker was verified immunohistochemically in invasive ductal breast cancer
In follow-up analyses of the sample of pts, the prognostic value of securin was compared with the established markers of breast cancer proliferation, Ki-67, and mitotic activity index (MAI)
Results of a small sample of pts suggest that low securin expression identifies a distinct subgroup of more favourable outcome among pts with high Ki-67 immunoexpression or high MAI
10-unit increment of securin immunopositivity was associated with a 2.3-fold overall risk of death due to breast cancer and a 7.1-fold risk of death due to breast cancer in the sample of pts stratified according to the cutoff points of 10% and 20% of securin immunopositivity
See all
